[특징주] Medytox,’weak’ on news of temporary suspension of manufacturing and sales of’Innotox stock’

[이코노믹리뷰=노성인 기자] Medytox (086900) is showing weakness in the news that the Ministry of Food and Drug Safety has issued an order to temporarily suspend the manufacture, sale, and use of botulinum toxin’Innotox’, a wrinkle-improving botulinum toxin.

On the 22nd, Medytox is trading at 17,100 won, down 19600 won (10.33%) from the previous trading day at 9:18 am.

Medytox explained, “The violation of the Pharmaceutical Affairs Act for’Innotox,’ which is manufactured and sold, was notified to the Ministry of Food and Drug Safety,” and said, “We received an order to suspend manufacturing and suspend sales temporarily in accordance with Article 71 of the Pharmaceutical Affairs Act.”

The prosecution has confirmed violations of forged safety test data in the process of Meditox’s drug product approval and modification through public interest reports, and has prosecuted him for obstructing the execution of public affairs by hierarchies under Article 137 of the Criminal Act.

On the 22nd, the Ministry of Food and Drug Safety confirmed the relevant items and violations after receiving notification of the licensed crime from the prosecution. In accordance with 3), it announced that it has begun the procedure for canceling the item permission.

On the other hand, Medytox is planning to file a lawsuit for suspension of validity and cancellation of orders to suspend manufacturing and sales in the future.